We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 10 augustus 2018

The Lancet: [Articles] Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an ...

[Articles] Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Mogamulizumab significantly prolonged progression-free survival compared with vorinostat, and could provide a new, effective treatment for patients with mycosis fungoides and, importantly, for S├ęzary syndrome, a subtype that represents a major therapeutic challenge in cutaneous T-cell lymphoma.
Read more

[Articles] Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sorafenib, when given orally in combination with topotecan and continued as maintenance therapy, showed a statistically and clinically significant improvement in progression-free survival in women with platinum-resistant ovarian cancer. These encouraging results support the crucial role of antiangiogenesis as the treatment backbone in combination with chemotherapy, making this approach attractive for further assessment with other targeted strategies.
Read more

[News] HPV status and oesophageal adenocarcinoma
Patients with Barrett's high-grade dysplasia and oesophageal adenocarcinoma who are positive for human papillomavirus (HPV) have improved survival outcomes and reduced recurrence and disease progression compared with those who are negative for HPV, according to a recent study.
Read more

[Comment] CCR4-targeted therapy in cutaneous T-cell lymphoma
Various neoplasms, including T-cell lymphomas and solid tumours, have high C-C chemokine receptor 4 (CCR4) expression. In physiological conditions, CCR4 plays a part in the homing of memory T cells to peripheral tissues, such as the skin.1 Importantly, cutaneous T-cell lymphomas, which arise from those skin resident memory lymphocytes, also express CCR4, opening avenues for therapeutic intervention.2
Read more

[Comment] Treatment of platinum refractory or resistant ovarian cancer
In The Lancet Oncology, Radoslav Chekerov and colleagues1 report the results of a randomised phase 2 trial of the efficacy and safety of adding sorafenib (an oral tyrosine kinase inhibitor of the VEGF receptor and Ras, Raf, MEK, and ERK signalling pathways) to topotecan during chemotherapy and in maintenance in recurrent platinum-resistant or platinum-refractory ovarian cancer.1 The investigators faced a clinically relevant issue for medical and gynaecological oncologists; for decades, this patient setting has represented a disappointing challenge considering the low proportion of patients who achieve a response to conventional cytotoxic drugs, and short duration of time to progression, even with the use of doublets, which led only to worsening of toxicity.
Read more